Kelly Lager
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kelly Lager has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Albert Van Geelen
Virus and Prion Research Unit, National Animal Disease Center, Agricultural Research Service, U.S. Department of Agriculture, Ames, IA 50010, USA
1 shared publication - Alexandra C. Buckley
Virus and Prion Research Unit, National Animal Disease Center, Agricultural Research Service, U.S. Department of Agriculture, Ames, IA 50010, USA
1 shared publication - Baoqing Guo
Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, USA
1 shared publication - Hanjun Kim
Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, USA
1 shared publication - Kyoung-Jin Yoon
Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, USA
1 shared publication - Nestor Montiel
Virus and Prion Research Unit, National Animal Disease Center, Agricultural Research Service, U.S. Department of Agriculture, Ames, IA 50010, USA
1 shared publication
Latest Publications
- Open Access
Characterization of the Antibody Response to Experimental Seneca Valley Virus (Senecavirus A) Infection: Initial and Subsequent Homologous Inoculation in Gilts
This study investigated antibody response to Seneca Valley virus (SVV) in 15 gilts following intranasal inoculation and subsequent homologous re-inoculation of 12 animals at 140–153 days post-primary inoculation (dppi). Serum–virus neutralization (SVN) antibodies reached peak levels at 8 dppi and persisted through 102 dppi. SVV-specific IgM became undetectable by 33 dppi, while IgA and IgG persisted through 102 dppi and remained detectable after re-inoculation. Western immunoblot analysis showed variations in prevalence and duration of antibody responses to individual SVV capsid proteins, with a consistent response to the 36 kDa protein (presumed VP2), which persisted through 102 dppi and for 43 days post-secondary inoculation. The VP2-specific antibody response persisted alongside sustained neutralizing antibody titers throughout the study period. Notably, no clinical signs, vesicular lesions, or viremia were detected following re-inoculation, suggesting homologous protection by prior immunity under the conditions of the study. These findings demonstrate that SVV infection elicits an early, long-lasting neutralizing antibody response. The persistent response to the presumed VP2 suggests VP2 as a candidate for targeted epitope mapping and further investigation in vaccine development studies.
Open AccessCharacterization of the Antibody Response to Experimental Seneca Valley Virus (Senecavirus A) Infection: Initial and Subsequent Homologous Inoculation in Gilts
This study investigated antibody response to Seneca Valley virus (SVV) in 15 gilts following intranasal inoculation and subsequent homologous re-inoculation of 12 animals at 140–153 days post-primary inoculation (dppi). Serum–virus neutralization (SVN) antibodies reached peak levels at 8 dppi and persisted through 102 dppi. SVV-specific IgM became undetectable by 33 dppi, while IgA and IgG persisted through 102 dppi and remained detectable after re-inoculation. Western immunoblot analysis showed variations in prevalence and duration of antibody responses to individual SVV capsid proteins, with a consistent response to the 36 kDa protein (presumed VP2), which persisted through 102 dppi and for 43 days post-secondary inoculation. The VP2-specific antibody response persisted alongside sustained neutralizing antibody titers throughout the study period. Notably, no clinical signs, vesicular lesions, or viremia were detected following re-inoculation, suggesting homologous protection by prior immunity under the conditions of the study. These findings demonstrate that SVV infection elicits an early, long-lasting neutralizing antibody response. The persistent response to the presumed VP2 suggests VP2 as a candidate for targeted epitope mapping and further investigation in vaccine development studies.